All peptides discussed on this page are sold by Webber Science for in vitro research purposes only. They are not intended for human or veterinary use. This content is provided for informational purposes and does not constitute medical advice.
Introduction
Tissue injury — whether to muscle, tendon, ligament, cartilage, or nerve — presents a complex biological challenge. The body’s native repair cascade involves inflammation, proliferation, and remodeling, but this process is often slow, incomplete, or dysregulated. Over the past two decades, a class of short-chain peptides has attracted significant research interest for their ability to modulate specific stages of the wound-healing and tissue-repair cascade.
This guide provides Canadian researchers with a science-first overview of the five most studied injury repair peptides available for laboratory investigation: BPC-157, TB-500, IGF-1 LR3, Thymosin Alpha-1, and GHK-Cu. For each compound, we review the mechanism of action, key preclinical findings, and current state of the research literature.
If you are looking to source any of these peptides for your lab, all are available from Webber Science with certificates of analysis and Canadian shipping.
BPC-157 (Body Protection Compound-157)
Mechanism of Action
BPC-157 is a 15-amino-acid sequence derived from a larger protein found in human gastric juice. Its mechanism of action is multi-modal and remains an active area of investigation. Key pathways identified in preclinical models include:
- Angiogenesis promotion — BPC-157 upregulates VEGF (vascular endothelial growth factor) and eNOS, accelerating new blood vessel formation at injury sites (Sikiric et al., 2018).
- NO pathway modulation — BPC-157 interacts with the nitric oxide system, which plays a central role in vasodilation and tissue perfusion during the proliferative phase of healing.
- Gastrointestinal protection — The peptide’s original characterization focused on its ability to protect gastric mucosa, a property mediated through prostaglandin and NO-dependent mechanisms.
Preclinical Research Highlights
- Tendon and ligament repair: Rat models of Achilles tendon transection showed significantly improved healing outcomes, including better-organized collagen fibre alignment and faster functional recovery.
- Muscle healing: In rat gastrocnemius muscle crush injury models, BPC-157 accelerated myofibril regeneration and reduced fibrosis.
- Nerve repair: Studies in rat sciatic nerve injury models demonstrated enhanced functional recovery, possibly through upregulation of growth-associated protein-43 (GAP-43).
Research Considerations
BPC-157 has a large body of animal data but no completed clinical trials in humans. Canadian researchers should note that most published studies use parenteral administration in rodent models, making translational extrapolation premature.
📘 Further reading: BPC-157 Complete Guide for Canadian Researchers
🛒 Source for your lab: BPC-157 — Webber Science
TB-500 (Thymosin Beta-4)
Mechanism of Action
TB-500 is the synthetic version of Thymosin Beta-4 (Tβ4), a 43-amino-acid naturally occurring peptide. Tβ4 is one of the most abundant actin-binding proteins in mammalian cells, and its repair-related mechanisms include:
- Actin polymerization regulation — Tβ4 sequesters G-actin monomers, enabling controlled filament assembly critical for cell migration during wound healing.
- Angiogenesis — Tβ4 stimulates endothelial cell migration and tube formation, independently of VEGF in some models.
- Anti-inflammatory effects — Tβ4 downregulates pro-inflammatory cytokines (TNF-α, IL-1β) and upregulates anti-inflammatory mediators.
- Stem cell mobilization — Some evidence suggests Tβ4 promotes differentiation of resident progenitor cells at injury sites.
Preclinical Research Highlights
- Cardiac repair: Mouse models of myocardial infarction showed improved cardiac function and reduced scar size with Tβ4 treatment (Smart et al., 2007).
- Dermal wound healing: Tβ4 accelerated re-epithelialization and collagen deposition in full-thickness wound models.
- Corneal repair: Topical Tβ4 improved epithelial wound closure in multiple species, leading to early-stage clinical investigation in ophthalmology.
Research Considerations
A Phase II clinical trial (RGN-352) for acute myocardial infarction was initiated but did not progress to Phase III. The research literature is strongest in dermal and cardiac wound-healing models.
📘 Related comparison: BPC-157 vs. TB-500 — Which Peptide for Your Research?
🛒 Source for your lab: TB-500 — Webber Science
IGF-1 LR3 (Insulin-Like Growth Factor-1 Long R3)
Mechanism of Action
IGF-1 LR3 is a modified analogue of native IGF-1 featuring an arginine substitution at position 3 and a 13-amino-acid extension at the N-terminus. These modifications reduce binding to IGF-binding proteins (IGFBPs), significantly extending its half-life in biological systems.
- PI3K/Akt signalling — IGF-1 activates the PI3K/Akt/mTOR pathway, which drives protein synthesis and cell proliferation.
- MAPK/ERK pathway — Parallel activation promotes cell differentiation and survival.
- Satellite cell activation — IGF-1 plays a critical role in muscle satellite cell proliferation and fusion, central to skeletal muscle regeneration.
Preclinical Research Highlights
- Muscle hypertrophy and repair: Transgenic mouse models overexpressing IGF-1 showed enhanced muscle regeneration after injury and resistance to age-related sarcopenia.
- Nerve regeneration: IGF-1 promoted neurite outgrowth and Schwann cell proliferation in peripheral nerve injury models.
- Cartilage repair: In vitro and in vivo data suggest IGF-1 stimulates chondrocyte proliferation and extracellular matrix synthesis.
Research Considerations
IGF-1 LR3’s reduced IGFBP binding means researchers must account for significantly altered pharmacokinetics compared to native IGF-1. Dose-response relationships in tissue-specific models require careful characterization.
🛒 Source for your lab: IGF-1 LR3 — Webber Science
Thymosin Alpha-1
Mechanism of Action
Thymosin Alpha-1 (Tα1) is a 28-amino-acid peptide originally isolated from thymus tissue. Unlike TB-500 (Thymosin Beta-4), Tα1 primarily modulates the immune system rather than acting on actin dynamics:
- T-cell activation and maturation — Tα1 promotes differentiation of CD4+ and CD8+ T cells and enhances T-cell receptor signalling.
- Dendritic cell modulation — Tα1 increases dendritic cell maturation and antigen presentation capacity.
- Cytokine regulation — Tα1 upregulates IL-2 and IFN-γ while modulating inflammatory cascades.
Preclinical and Clinical Research
- Infection models: Tα1 has been studied extensively in chronic viral infections (hepatitis B and C), with several randomized controlled trials published.
- Immune dysfunction: In models of chemotherapy-induced immunosuppression, Tα1 accelerated immune reconstitution.
- Wound healing (indirect): By resolving chronic inflammation, Tα1 may indirectly support tissue repair processes stalled by immune dysregulation.
Thymosin Alpha-1 is one of the few peptides on this list with actual clinical data, having been approved in several countries (not Canada) as an adjunct therapy for hepatitis B and certain cancers. However, its wound-healing applications remain predominantly preclinical.
🛒 Source for your lab: Thymosin Alpha-1 — Webber Science
GHK-Cu (Copper Peptide-1)
Mechanism of Action
GHK-Cu is a tripeptide (glycyl-L-histidyl-L-lysine) that forms a natural complex with copper(II) ions. The copper-bound form is biologically active and mediates several repair-relevant processes:
- Collagen and elastin synthesis — GHK-Cu upregulates type I and III collagen genes and elastin expression in dermal fibroblasts.
- Angiogenesis — GHK-Cu stimulates VEGF and FGF-2 expression, promoting vascularization.
- Anti-inflammatory effects — GHK-Cu suppresses TNF-α, IL-1β, and IL-6 while upregulating anti-inflammatory signals.
- Antioxidant activity — The copper centre exhibits superoxide dismutase (SOD)-mimetic activity, reducing oxidative damage.
Preclinical Research Highlights
- Dermal wound healing: Human and animal studies demonstrate accelerated wound closure with topical GHK-Cu.
- Tissue remodeling: Gene expression profiling shows GHK-Cu upregulates over 500 genes related to tissue repair and downregulates inflammatory and degenerative genes (Pickart et al., 2015).
- Bone repair: In vitro data show GHK-Cu promotes osteoblast differentiation and mineralization.
Research Considerations
GHK-Cu’s utility is tightly linked to copper bioavailability. Researchers must consider copper status in their experimental models, as the peptide’s mechanism depends on the metal ion complex. Free GHK without copper has markedly reduced activity.
🛒 Source for your lab: GHK-Cu — Webber Science
Combining Injury Repair Peptides: The Wolverine Stack
One of the most commonly investigated combinations in the research community is the concurrent administration of BPC-157 and TB-500 — sometimes referred to as the “Wolverine Stack.” The rationale is complementary rather than redundant:
| Property | BPC-157 | TB-500 |
|—|—|—|
| Primary target | GI mucosa, endothelium | Actin, cell migration |
| Angiogenesis | VEGF/eNOS pathway | Endothelial migration |
| Anti-inflammatory | Prostaglandin-mediated | Cytokine modulation |
| Blood vessel repair | Strong evidence | Moderate evidence |
By targeting different nodes in the tissue-repair network, the combination produces additive effects in multiple animal models.
📘 Deep dive: The Wolverine Stack Explained: BPC-157 + TB-500 Q&A Guide
Choosing the Right Peptide for Your Research
Selecting the appropriate peptide depends on the tissue type, injury model, and research question:
- Tendon/ligament models → BPC-157 and TB-500 have the most robust data.
- Muscle repair → IGF-1 LR3 and BPC-157 dominate the literature.
- Dermal wound healing → GHK-Cu and TB-500 are best characterized.
- Immune-mediated chronic injury → Thymosin Alpha-1 warrants investigation.
- Angiogenesis studies → BPC-157, TB-500, and GHK-Cu all modulate distinct angiogenic pathways.
For research teams investigating muscle recovery and joint health, our related guides may provide additional context:
- Peptides for Muscle Recovery: A Complete Guide for Athletes
- Joint Health and Peptides: Natural Solutions for Pain Relief
Sourcing Injury Repair Peptides in Canada
Canadian research labs face specific considerations when sourcing peptides:
1. Regulatory compliance — Peptides must be labelled for research use only and not marketed for human consumption. Health Canada regulates peptide drugs under the Food and Drugs Act.
2. Purity and COA — Reputable suppliers provide third-party certificates of analysis confirming peptide identity, purity (≥98%), and absence of contaminants.
3. Cold-chain shipping — Most injury repair peptides are stable at room temperature in lyophilized form but require refrigeration after reconstitution.
4. Customs and import — Peptides imported into Canada must comply with CBSA requirements; domestic sourcing simplifies logistics.
Webber Science is a Canadian-based supplier offering all five peptides discussed in this guide with full certificates of analysis and domestic shipping.
FAQ
Are injury repair peptides approved for human use in Canada?
No. None of the peptides discussed on this page — BPC-157, TB-500, IGF-1 LR3, Thymosin Alpha-1, or GHK-Cu — are approved by Health Canada for human therapeutic use. They are supplied for in vitro and preclinical laboratory research only.
What is the most studied injury repair peptide?
BPC-157 has the largest body of preclinical literature related to tissue repair, with over 100 published studies across tendon, muscle, ligament, nerve, and gastrointestinal models. Thymosin Alpha-1 has the most clinical data, but its clinical use relates to immunomodulation rather than direct wound healing.
Can BPC-157 and TB-500 be used together in research?
Yes. Concurrent administration of BPC-157 and TB-500 is a common research protocol, as the two peptides target non-overlapping mechanisms in the tissue-repair cascade. See our Wolverine Stack guide for details.
What concentration should researchers use for BPC-157?
Published preclinical studies typically use doses in the range of 1–10 μg/kg in rodent models. However, optimal concentration depends on the specific tissue model, route of administration, and experimental design. Researchers should consult primary literature for their specific application.
Does GHK-Cu require copper to be active?
Yes. The biological activity of GHK-Cu depends on its copper(II) complex. Free GHK (without copper) has significantly reduced activity in most assay systems.
How should injury repair peptides be stored?
Lyophilized peptides should be stored at −20°C in a desiccated environment. After reconstitution with sterile bacteriostatic water, aliquots should be stored at 2–8°C and used within the timeframe indicated on the product’s certificate of analysis.
Browse Injury Repair Peptides
Ready to source peptides for your research? Explore the full catalogue at Webber Science:
All products are for research purposes only. Not for human or veterinary use.
References
- Sikiric, P. et al. (2018). “Peptide therapy with BPC 157 in tissue repair.” *International Journal of Molecular Sciences*, 19(4), 1128.
- Smart, N. et al. (2007). “Thymosin beta4 induces adult epicardial progenitor mobilization and neovascularization.” *Nature*, 445, 177–182.
- Pickart, L. et al. (2015). “GHK-Cu: a human copper-binding peptide with multiple roles in tissue repair.” *Journal of Aging Research & Lifestyle*, 4, 44–52.
- Goldstein, A.L. et al. (2012). “Thymosin α1: a peptide immune modulator with broad clinical applications.” *Expert Opinion on Biological Therapy*, 12(6), 763–776.